Kunter Uta, Rong Song, Djuric Zivka, Boor Peter, Müller-Newen Gerhard, Yu Donghai, Floege Jürgen
Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
J Am Soc Nephrol. 2006 Aug;17(8):2202-12. doi: 10.1681/ASN.2005080815. Epub 2006 Jun 21.
Bone marrow-derived cells contribute to glomerular cell turnover and repair, but the cell types involved are unknown. Whether rat mesenchymal stem cells (MSC) can accelerate recovery from damage in rat mesangioproliferative anti-Thy1.1 glomerulonephritis was studied. After injection into the left renal artery on day 2 after disease induction, fluorescently labeled MSC were detected in 20 to 50% of glomeruli and rare intrarenal vessels but not in the tubulointerstitium, in contralateral kidneys, or in medium controls. In control experiments, injected mesangial cells were detected less frequently in glomeruli in comparison with injected MSC. In nephritic outbred Wistar rats, MSC injection led to an approximately 50% reduction of mesangiolysis on days 4 and 6 after disease induction, accompanied by three- to four-fold higher intraglomerular cell proliferation on day 4 and more rapid mesangial reconstitution as detected by alpha-smooth muscle actin expression. Injection of MSC into tail veins or intra-arterial injection of mesangial cells instead of MSC failed to reproduce any of these findings. In inbred Lewis rats, anti-Thy1.1 nephritis followed an aggravated course with transient acute renal failure. Acute renal failure was ameliorated by MSC injection into the left renal artery on day 2 after disease induction. Again, MSC led to more rapid recovery from mesangiolysis, increased glomerular cell proliferation, and reduction of proteinuria by 28%. Double immunostaining of 5-bromo-2'-deoxyuridine-labeled MSC for endothelial, mesangial, or monocyte/macrophage antigens showed that 85 to 95% of MSC that localized in glomeruli on day 6 failed to express these markers. In vitro, MSC secreted high amounts of vascular endothelial growth factor and TGF-beta1 but not PDGF-BB. In conclusion, even low numbers of MSC can markedly accelerate glomerular recovery from mesangiolytic damage possibly related to paracrine growth factor release and not to differentiation into resident glomerular cell types or monocytes/macrophages.
骨髓来源的细胞参与肾小球细胞的更新和修复,但其中涉及的细胞类型尚不清楚。研究了大鼠间充质干细胞(MSC)是否能加速大鼠系膜增生性抗Thy1.1肾小球肾炎损伤后的恢复。在疾病诱导后第2天经左肾动脉注射后,在20%至50%的肾小球和罕见的肾内血管中检测到荧光标记的MSC,但在肾小管间质、对侧肾脏或培养基对照中未检测到。在对照实验中,与注射的MSC相比,注射的系膜细胞在肾小球中的检测频率较低。在患有肾炎的远交系Wistar大鼠中,MSC注射导致疾病诱导后第4天和第6天系膜溶解减少约50%,第4天肾小球内细胞增殖增加三到四倍,并且通过α-平滑肌肌动蛋白表达检测到系膜重建更快。将MSC注入尾静脉或动脉内注射系膜细胞而非MSC均未能重现上述任何结果。在近交系Lewis大鼠中,抗Thy1.1肾炎病情加重并伴有短暂性急性肾衰竭。在疾病诱导后第2天经左肾动脉注射MSC可改善急性肾衰竭。同样,MSC可使系膜溶解恢复更快,肾小球细胞增殖增加,蛋白尿减少28%。对5-溴-2'-脱氧尿苷标记的MSC进行内皮、系膜或单核细胞/巨噬细胞抗原的双重免疫染色显示,第6天位于肾小球内的MSC中85%至95%不表达这些标志物。在体外,MSC分泌大量血管内皮生长因子和转化生长因子-β1,但不分泌血小板源性生长因子-BB。总之,即使少量的MSC也能显著加速肾小球从系膜溶解损伤中恢复,这可能与旁分泌生长因子释放有关,而不是分化为驻留的肾小球细胞类型或单核细胞/巨噬细胞。